Absci Corp (NASDAQ:ABSI)
3.9 USD
+0.210 5.691%Sponsored Reports
Previous Close (in USD) | 3.69 |
---|---|
Change | +0.210 5.691% |
52 W H/L (in USD) | 6.720/1.111 |
EBITDA (in USD) | -79.681M |
PE Ratio | -- |
Volume | 590402 |
Diluted Eps TTM | -1.16 |
Total Assets (in USD) | 234.48M |
---|---|
Total Liabilities (in USD) | 58.304M |
Revenue TTM (in USD) | 5.718M |
Cash (in USD) | 88.555M |
Market Cap (in USD) | 498.474 M |
Revenue Per Share TTM | 0.062 |
Gross Profit TTM (in USD) | -39.804M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Absci Corp
18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683
360 949 1041
Employees: 155
Key Executives
Sr. No. | Name | Title | Year Born |
---|---|---|---|
1. | Mr. Sean McClain | Founder, CEO, Pres & Director | 1991 |
2. | Dr. Sarah Korman J.D., Ph.D. | Chief Legal Officer & Corp. Sec. | 1979 |
3. | Mr. Gregory T. Schiffman CPA, CPA, MBA | Chief Financial Officer | 1957 |
4. | Todd Bedrick CPA | Sr. VP & Chief Accounting Officer | NA |
5. | Mr. Jack Gold | Chief Marketing Officer | NA |
6. | Melissa Patterson Ph.D. | Chief of Staff | NA |
7. | Ms. Denise Dettore | Chief People Officer | NA |
8. | Dr. Andreas Busch Ph.D. | Chief Innovation Officer | 1963 |
9. | Jonathan Eads M.S. | Sr. VP of Informatics | NA |
10. | Thomas Wrona J.D., Ph.D. | Sr. VP of Intellectual Property | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
NVO
Novo Nordisk A/S |
+0.340 0.249% | 136.86 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
NONOF
Novo Nordisk A/S |
-1.250 0.904% | 137 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
VRTX
Vertex Pharmaceuticals Inc |
+6.720 1.404% | 480 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
REGN
Regeneron Pharmaceuticals Inc |
-11.110 0.954% | 1160.74 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|
Income Before Tax | -105.365M | -109.859M | -14.353M | -6.584M |
Minority Interest | - | - | - | - |
Net Income | -104.904M | -100.96M | -14.569M | -6.801M |
Selling General Administrative | 40.552M | 28.78M | 5.502M | 3.523M |
Gross Profit | 5.747M | 4.782M | 4.78M | 2.06M |
Reconciled Depreciation | 13.037M | 6.654M | 1.131M | 0.491M |
Ebit | -106.75M | -75.238M | -13.301M | -6.265M |
Ebitda | -91.356M | -99.773M | -12.588M | -5.825M |
Depreciation And Amortization | 15.394M | -24.535M | 0.713M | 0.44M |
Operating Income | -106.75M | -75.238M | -13.301M | -6.265M |
Other Operating Expenses | 112.497M | 80.02M | 18.081M | 8.325M |
Interest Expense | 0.972M | 3.432M | 0.634M | 0.268M |
Tax Provision | -0.461M | -8.899M | - | - |
Interest Income | - | - | - | - |
Net Interest Income | -0.972M | -3.432M | -0.634M | -0.268M |
Income Tax Expense | -0.461M | -8.899M | 0.216M | 0.217M |
Total Revenue | 5.747M | 4.782M | 4.78M | 2.06M |
Total Operating Expenses | 112.497M | 80.02M | 18.081M | 8.325M |
Cost Of Revenue | - | 6.654M | - | - |
Total Other Income Expense Net | 1.385M | -34.621M | -1.052M | -0.319M |
Net Income From Continuing Ops | -104.904M | -100.96M | -14.353M | -6.584M |
Net Income Applicable To Common Shares | -104.904M | -103.244M | -49.469M | -23.87M |
Balance Sheet
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Total Assets | 234.48M | 321.008M | 426.195M | 88.569M | 19.471M |
Intangible Assets | 48.253M | 51.622M | 54.992M | 0.188M | 0.283M |
Other Current Assets | 4.537M | 5.859M | 8.572M | 1.773M | 0.339M |
Total Liab | 58.304M | 46.594M | 60.088M | 177.997M | 60.63M |
Total Stockholder Equity | 176.176M | 274.414M | 366.107M | -89.428M | -41.159M |
Other Current Liab | 19.303M | 20.481M | 17.434M | 1.569M | 0.532M |
Common Stock | 0.009M | 0.009M | 0.009M | 0.002M | 0.002M |
Capital Stock | 0.009M | 0.009M | 0.009M | 0.002M | 0.002M |
Retained Earnings | -406.495M | -295.929M | -191.025M | -90.065M | -41.376M |
Good Will | 0M | 21.335M | 21.335M | - | - |
Other Assets | 0M | 3.146M | 18.137M | 1.95M | 0.814M |
Cash | 88.555M | 59.955M | 252.569M | 69.867M | 13.086M |
Cash And Equivalents | - | - | - | - | - |
Total Current Liabilities | 29.558M | 30.27M | 33.859M | 10.095M | 3.466M |
Current Deferred Revenue | 3.174M | 0.445M | 1.353M | 2.63M | 0.78M |
Net Debt | -72.598M | -36.972M | -232.558M | -55.367M | -7.07M |
Short Term Debt | 5.578M | 6.932M | 6.687M | 3.78M | 1.886M |
Short Long Term Debt | 3.258M | 2.946M | 2.4M | 1.535M | 1.2M |
Short Long Term Debt Total | 15.957M | 22.983M | 20.011M | 14.5M | 6.016M |
Other Stockholder Equity | 582.699M | 570.454M | 130.941M | 0.635M | 0.215M |
Property Plant Equipment | - | 58.042M | 58.652M | 13.385M | 5.01M |
Total Current Assets | 120.578M | 186.863M | 273.079M | 73.234M | 13.647M |
Long Term Investments | - | - | - | - | - |
Short Term Investments | 25.297M | 104.476M | - | - | - |
Net Receivables | 2.189M | 1.55M | 1.425M | 1.594M | 0.222M |
Long Term Debt | 4.66M | 7.984M | 1.124M | 4.141M | 1.746M |
Inventory | - | 15.023M | 10.513M | - | - |
Accounts Payable | 1.503M | 2.412M | 8.385M | 2.116M | 0.268M |
Accumulated Other Comprehensive Income | -0.037M | -0.12M | -0.013M | - | - |
Non Currrent Assets Other | 1.537M | 3.146M | 18.137M | 1.762M | 0.531M |
Non Current Assets Total | 113.902M | 134.145M | 153.116M | 15.335M | 5.824M |
Capital Lease Obligations | 8.039M | 12.053M | 16.487M | 8.824M | 3.07M |
Long Term Debt Total | - | - | 1.124M | - | - |
Cash Flow
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|
Investments | -126.982M | -1.2M | -2.171M | -1.089M |
Total Cashflows From Investing Activities | -126.982M | -67.377M | -2.171M | -1.089M |
Total Cash From Financing Activities | 5.237M | 336.193M | 70.973M | 12.706M |
Net Income | -104.904M | -100.96M | -14.353M | -6.584M |
Change In Cash | -203.084M | 208.218M | 57.832M | 5.585M |
Begin Period Cash Flow | 279.926M | 71.708M | 13.876M | 8.291M |
End Period Cash Flow | 76.842M | 279.926M | 71.708M | 13.876M |
Total Cash From Operating Activities | -81.339M | -60.598M | -10.97M | -6.032M |
Depreciation | 13.037M | 6.654M | 1.131M | 0.491M |
Other Cashflows From Investing Activities | 0.65M | -29.33M | 0.65M | 0.65M |
Dividends Paid | - | - | - | - |
Change To Inventory | - | - | - | - |
Sale Purchase Of Stock | - | 210.396M | - | - |
Other Cashflows From Financing Activities | 12.031M | 129.944M | 72.564M | 13.083M |
Capital Expenditures | 16.175M | 38.047M | 2.181M | 1.098M |
Change In Working Capital | -1.54M | -3.146M | 1.008M | -0.089M |
Other Non Cash Items | 0.033M | 35.147M | 0.824M | 0.108M |
Free Cash Flow | -97.514M | -98.645M | -13.151M | -7.13M |
Funds
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | Fidelity Growth Company Fund | 5 months ago | 4177046 |
2. | Alger Small Cap Focus Composite | 5 months ago | 5806794 |
3. | Fidelity Growth Compy Commingled Pl O | 5 months ago | 5731707 |
4. | Alger Small Cap Focus I | 6 months ago | 4284772 |
5. | ARK Genomic Revolution ETF | 4 months ago | 3278030 |
6. | ARK Genomic Revolution | 5 months ago | 3246132 |
7. | Vanguard Total Stock Mkt Idx Inv | 5 months ago | 2410195 |
8. | Fidelity Growth Company K6 | 5 months ago | 1585965 |
9. | Fidelity Select Biotechnology | 5 months ago | 1102700 |
10. | Fidelity Series Growth Company | 5 months ago | 1084333 |
11. | Vanguard Institutional Extnd Mkt Idx Tr | 5 months ago | 913421 |
12. | Fidelity Small Cap Growth | 6 months ago | 808377 |
13. | Alger Small Cap Growth B | 6 months ago | 467626 |
14. | Victory Science & Technology | 5 months ago | 452700 |
15. | Fidelity Extended Market Index | 5 months ago | 365112 |
16. | Fidelity Small Cap Growth K6 | 6 months ago | 320326 |
17. | Schwab US Small-Cap ETF™ | 4 months ago | 297768 |
18. | Alger Small Cap Growth I-2 | 6 months ago | 232996 |
19. | Alger Small Cap Growth Institutional I | 6 months ago | 182199 |
20. | Alger Small Cap Growth Composite | 5 months ago | 174797 |
Institutions
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | FMR Inc | 8 months ago | 13861521 |
2. | Redmile Group, LLC | 5 months ago | 8253316 |
3. | Fred Alger Management, LLC | 5 months ago | 7407809 |
4. | Vanguard Group Inc | 5 months ago | 3445272 |
5. | ARK Investment Management LLC | 5 months ago | 3277094 |
6. | Millennium Management LLC | 5 months ago | 1769994 |
7. | Marshall Wace Asset Management Ltd | 5 months ago | 1486823 |
8. | Woodline Partners LP | 5 months ago | 1474185 |
9. | LAURION CAPITAL MANAGEMENT LP | 5 months ago | 1186427 |
10. | Casdin Capital, LLC | 8 months ago | 973260 |
11. | BlackRock Inc | 8 months ago | 845724 |
12. | Junked Platinum Investment Management Ltd | 5 months ago | 776602 |
13. | Perceptive Advisors LLC | 5 months ago | 700000 |
14. | Boxer Capital LLC | 5 months ago | 700000 |
15. | Geode Capital Management, LLC | 8 months ago | 662681 |
16. | Nikko Asset Management Americas Inc | 5 months ago | 420812 |
17. | Sumitomo Mitsui Trust Holdings Inc | 5 months ago | 420812 |
18. | HSBC Holdings PLC | 5 months ago | 407579 |
19. | D. E. Shaw & Co LP | 5 months ago | 397033 |
20. | Charles Schwab Investment Management Inc | 5 months ago | 351403 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).